Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.33 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689807 | 0.91 | ACACB (0.39) | ANO1SHMT1SHMT2SLC6A3 | |
| SCHEMBL12457529 | 0.91 | ACACB (0.39) | ANO1SHMT1SHMT2SLC6A3 | |
| SCHEMBL2353770 | 0.91 | ACACB (0.39) | ANO1SHMT1SHMT2SLC6A3 | |
| SCHEMBL12458145 | 0.89 | ANO1 (0.38) | ANO1SHMT1SHMT2SLC6A3P2RX7 | |
| SCHEMBL14689724 | 0.89 | ANO1 (0.38) | ANO1SHMT1SHMT2SLC6A3P2RX7 | |
| SCHEMBL2350931 | 0.89 | ANO1 (0.38) | ANO1SHMT1SHMT2SLC6A3P2RX7 | |
| SCHEMBL2353473 | 0.88 | ANO1 (0.39) | ANO1SHMT1SHMT2SLC6A3TRPV1 | |
| SCHEMBL14689906 | 0.88 | ACACB (0.40) | ANO1SHMT1SHMT2SLC6A3 | |
| SCHEMBL2349298 | 0.88 | ACACB (0.40) | ANO1SHMT1SHMT2SLC6A3 | |
| SCHEMBL12458435 | 0.88 | ACACB (0.40) | ANO1SHMT1SHMT2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| EP-2536686-A1 | CYCLIC KETO-ENOLS FOR THERAPY | Bayer Intellectual Property GmbH (DE) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011098433-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011098433-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | AKR1B1, AKR1C3, AKR1A1 | ANO1 3557/4885GHSR 2123/4885GAA 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.